Morphine transdermal - Teika Pharmaceutical

Drug Profile

Morphine transdermal - Teika Pharmaceutical

Latest Information Update: 19 Jan 2015

Price : $50

At a glance

  • Originator Teika Pharmaceutical
  • Class Morphinans; Opioid analgesics; Small molecules
  • Mechanism of Action Opioid mu receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Clinical Phase Unknown Pain

Most Recent Events

  • 11 Sep 2013 Biomarkers information updated
  • 01 Jun 2009 Clinical trials in Pain in Japan (Transdermal)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top